Ignite Creation Date:
2024-05-06 @ 7:33 PM
Last Modification Date:
2024-10-26 @ 3:09 PM
Study NCT ID:
NCT06059118
Status:
RECRUITING
Last Update Posted:
2024-02-14
First Post:
2023-09-15
Brief Title:
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Organization:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study Overview
Official Title:
Repeat Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Asymptomatic Patients With Metastatic Castration-Resistant Prostate Cancer The APEX Androgen and Polyamine Elimination Alternating With Xtandi Trial
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Asymptomatic patients with metastatic castrate resistant prostate cancer mCRPC without pain due to prostate cancer will be treated on an open label study to evaluate effectiveness of sequential treatment with the combination of difluoromethylornithine DFMO and high dose testosterone in sequence with enzalutamide to improve primary and secondary outcomes
Detailed Description:
Eligible patients are those with mCRPC who have progressive disease after treatment with Abiraterone Abi used as treatment for castration-sensitive or castration-resistant disease Patients will continue on androgen deprivation therapy ADT with luteinizing hormone-releasing hormone LHRH agonist ie Zoladex Trelstar Eligard or Lupron or LHRH antagonist Degarelix or Relugolix if not surgically castrated throughout the duration of the study to inhibit endogenous testosterone production One cycle of treatment will be 119 days and will involve
1 7 days of DFMO at a dose of 1000 mg PO BID D1-D7 followed by
2 56 days of combined testosterone and DFMO testosterone cypionate 400 mg IM on D8 and D36 with continued DFMO 1000 mg PO BID D8-D63 followed by
3 56 days of enzalutamide enzalutamide 160 mg PO daily D64-D119
Patients will receive repeat cycles of treatment until clinical or radiographic progression or toxicity requiring drug cessation
1 7 days of DFMO at a dose of 1000 mg PO BID D1-D7 followed by
2 56 days of combined testosterone and DFMO testosterone cypionate 400 mg IM on D8 and D36 with continued DFMO 1000 mg PO BID D8-D63 followed by
3 56 days of enzalutamide enzalutamide 160 mg PO daily D64-D119
Patients will receive repeat cycles of treatment until clinical or radiographic progression or toxicity requiring drug cessation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| IRB00371517 | OTHER | JHM IRB | None |